The StoneBreakerTM Trial
The Canadian StoneBreakerTM Trial: A Randomized, Multicentre Trial Comparing The LMA StoneBreakerTM and the Swiss LithoClastR During Percutaneous Nephrolithotripsy.
1 other identifier
interventional
40
1 country
1
Brief Summary
The purpose of this study is to compare the LMA StoneBreakerTM to the current standard of pneumatic lithotripsy, the Swiss LithoClastR, during percutaneous nephrolithotripsy (PNL).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Feb 2008
Typical duration for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2008
CompletedFirst Submitted
Initial submission to the registry
May 12, 2008
CompletedFirst Posted
Study publicly available on registry
May 14, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2010
CompletedSeptember 27, 2010
September 1, 2010
2.6 years
May 12, 2008
September 23, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time to complete fragmentation of renal calculi treated via PNL
During surgery
Secondary Outcomes (1)
Time to removal of large fragments using graspers & time required with US to remove small fragments/dust
During surgery
Study Arms (2)
1
ACTIVE COMPARATORThe LMA StoneBreakerTM
2
ACTIVE COMPARATORPneumatic Lithotripsy
Interventions
The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
Eligibility Criteria
You may qualify if:
- Patients over the age of 18 undergoing PNL
- Previously untreated renal stones
- Patients with 3 or less individual renal calculi, accessible with a rigid nephroscope
- Stones must be at least \>225mm2 area on KUB
- Patient must have a CT scan prior to treatment
You may not qualify if:
- Patients with an active contraindication for PNL (pregnancy, uncorrected coagulopathy, active urinary infection, contrast allergy)
- Partial staghorn calculi
- Complete staghorn calculi
- Stones in calyceal diverticulum
- Cases requiring multiple tracts
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of British Columbialead
- VGH and UBC Hospital Foundationcollaborator
- Vancouver Coastal Healthcollaborator
Study Sites (1)
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Ben Chew, MD, FRCSC
University of British Columbia
- STUDY DIRECTOR
R. Paterson, MD
University of British Columbia
- STUDY DIRECTOR
J. Wright, MD
University of British Columbia
- STUDY DIRECTOR
J. Teichman, MD
University of British Columbia
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 12, 2008
First Posted
May 14, 2008
Study Start
February 1, 2008
Primary Completion
September 1, 2010
Study Completion
September 1, 2010
Last Updated
September 27, 2010
Record last verified: 2010-09